Ana Isabel Ferreira, C. Arieira, S. Xavier, J. Cotter
{"title":"S42 Tailoring Crohn’s Disease Surveillance After Ileocolic Resection: The Importance of Inflammatory Biomarkers","authors":"Ana Isabel Ferreira, C. Arieira, S. Xavier, J. Cotter","doi":"10.14309/01.ajg.0000995908.19720.68","DOIUrl":null,"url":null,"abstract":", immunohistochemical staining for IgG4 was performed on the patient ’ s colon biopsies, which revealed a high percentage of the IgG cells in the lamina propria with . 50% positivity for IgG4. This con fi rmed the patient ’ s IgG4 mediated colitis, and he has now started rituximab therapy. Conclusions: We demonstrate a case of IgG4-RD misclassi fi ed as CD and GPA and emphasize the importance of consideration of this rare disorder in appropriate patients. Clinical follow-up and response to rituximab will be described at the time of this case presentation.","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"102 ","pages":"S12 - S12"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000995908.19720.68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
, immunohistochemical staining for IgG4 was performed on the patient ’ s colon biopsies, which revealed a high percentage of the IgG cells in the lamina propria with . 50% positivity for IgG4. This con fi rmed the patient ’ s IgG4 mediated colitis, and he has now started rituximab therapy. Conclusions: We demonstrate a case of IgG4-RD misclassi fi ed as CD and GPA and emphasize the importance of consideration of this rare disorder in appropriate patients. Clinical follow-up and response to rituximab will be described at the time of this case presentation.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
